215 related articles for article (PubMed ID: 14598055)
21. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile.
Dalakas MC
Pharmacol Ther; 2004 Jun; 102(3):177-93. PubMed ID: 15246245
[TBL] [Abstract][Full Text] [Related]
22. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments.
Basta M; Dalakas MC
J Clin Invest; 1994 Nov; 94(5):1729-35. PubMed ID: 7962520
[TBL] [Abstract][Full Text] [Related]
23. Platelet-endothelial cell adhesion molecule-1 and CD146: soluble levels and in situ expression of cellular adhesion molecules implicated in the cohesion of endothelial cells in idiopathic inflammatory myopathies.
Figarella-Branger D; Schleinitz N; Boutière-Albanèse B; Camoin L; Bardin N; Guis S; Pouget J; Cognet C; Pellissier JF; Dignat-George F
J Rheumatol; 2006 Aug; 33(8):1623-30. PubMed ID: 16881117
[TBL] [Abstract][Full Text] [Related]
24. Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis: a series of 73 patients.
Marie I; Menard JF; Hatron PY; Hachulla E; Mouthon L; Tiev K; Ducrotte P; Cherin P
Arthritis Care Res (Hoboken); 2010 Dec; 62(12):1748-55. PubMed ID: 20722047
[TBL] [Abstract][Full Text] [Related]
25. Potential therapeutic targets for idiopathic inflammatory myopathies.
De Bleecker JL; Creus KK; De Paepe B
Drug News Perspect; 2006 Nov; 19(9):549-57. PubMed ID: 17220960
[TBL] [Abstract][Full Text] [Related]
26. [Current therapy for polymyositis and dermatomyositis].
Chérin P
Rev Med Interne; 2008 Jun; 29 Spec No 2():9-14. PubMed ID: 18927983
[TBL] [Abstract][Full Text] [Related]
27. Inflammatory myopathies: clinical, diagnostic and therapeutic aspects.
Mastaglia FL; Garlepp MJ; Phillips BA; Zilko PJ
Muscle Nerve; 2003 Apr; 27(4):407-25. PubMed ID: 12661042
[TBL] [Abstract][Full Text] [Related]
28. Intravenous Immunoglobulin in Idiopathic Inflammatory Myopathies: a Practical Guide for Clinical Use.
Gandiga PC; Ghetie D; Anderson E; Aggrawal R
Curr Rheumatol Rep; 2023 Aug; 25(8):152-168. PubMed ID: 37261663
[TBL] [Abstract][Full Text] [Related]
29. How to diagnose and treat the inflammatory myopathies.
Dalakas MC
Semin Neurol; 1994 Jun; 14(2):137-45. PubMed ID: 7984828
[TBL] [Abstract][Full Text] [Related]
30. Inflammatory myopathies: management of steroid resistance.
Dalakas MC
Curr Opin Neurol; 2011 Oct; 24(5):457-62. PubMed ID: 21799409
[TBL] [Abstract][Full Text] [Related]
31. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM.
Chahin N; Engel AG
Neurology; 2008 Feb; 70(6):418-24. PubMed ID: 17881720
[TBL] [Abstract][Full Text] [Related]
32. High dose intravenous immunoglobulin (IVIG) in dermatomyositis: clinical responses and effect on sIL-2R levels.
Göttfried I; Seeber A; Anegg B; Rieger A; Stingl G; Volc-Platzer B
Eur J Dermatol; 2000; 10(1):29-35. PubMed ID: 10694294
[TBL] [Abstract][Full Text] [Related]
33. Exercise effects in patients with adult idiopathic inflammatory myopathies.
Alexanderson H
Curr Opin Rheumatol; 2009 Mar; 21(2):158-63. PubMed ID: 19339927
[TBL] [Abstract][Full Text] [Related]
34. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM.
Dalakas MC; Koffman B; Fujii M; Spector S; Sivakumar K; Cupler E
Neurology; 2001 Feb; 56(3):323-7. PubMed ID: 11171896
[TBL] [Abstract][Full Text] [Related]
35. Update on idiopathic inflammatory myopathies.
Briani C; Doria A; Sarzi-Puttini P; Dalakas MC
Autoimmunity; 2006 May; 39(3):161-70. PubMed ID: 16769649
[TBL] [Abstract][Full Text] [Related]
36. Immunopathogenesis of inflammatory myopathies.
Dalakas MC
Ann Neurol; 1995 May; 37 Suppl 1():S74-86. PubMed ID: 8968219
[TBL] [Abstract][Full Text] [Related]
37. Pilot trial of etanercept in the treatment of inclusion-body myositis.
Barohn RJ; Herbelin L; Kissel JT; King W; McVey AL; Saperstein DS; Mendell JR
Neurology; 2006 Jan; 66(2 Suppl 1):S123-4. PubMed ID: 16432140
[TBL] [Abstract][Full Text] [Related]
38. Intravenous immunoglobulin therapy in adult patients with polymyositis/dermatomyositis: a systematic literature review.
Wang DX; Shu XM; Tian XL; Chen F; Zu N; Ma L; Wang GC
Clin Rheumatol; 2012 May; 31(5):801-6. PubMed ID: 22274797
[TBL] [Abstract][Full Text] [Related]
39. Plasma cells in muscle in inclusion body myositis and polymyositis.
Greenberg SA; Bradshaw EM; Pinkus JL; Pinkus GS; Burleson T; Due B; Bregoli L; O'Connor KC; Amato AA
Neurology; 2005 Dec; 65(11):1782-7. PubMed ID: 16344523
[TBL] [Abstract][Full Text] [Related]
40. [Polymyositis: disease course and therapy with intravenously administered immunoglobulins].
Stoll T; Michel BA; Neidhart M; Wassmer P; Neidl K; Fehr K; Wagenhäuser FJ
Schweiz Med Wochenschr; 1992 Sep; 122(39):1458-65. PubMed ID: 1411405
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
